Versant Capital Management’s Novavax NVAX Stock Holding History

Versant Capital Management’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$7.23K	Sell	669 -11	-2%	-$99	﹤0.01%	2365
2026 Q2	$6.41K	Sell	680 -575	-46%	-$5.15K	﹤0.01%	2373
2026 Q1	$10.2K	Buy	1,255 +586	+88%	+$5.31K	﹤0.01%	2135
2025 Q4	$4.5K	Sell	669 -158	-19%	-$1.19K	﹤0.01%	2289
2025 Q3	$7.17K	Hold	827	–	–	﹤0.01%	2069
2025 Q2	$5.21K	Buy	+827	New	+$5.48K	﹤0.01%	2135
2022 Q1	–	Sell	-2	Closed	–	–	1571
2021 Q4	$0	Sell	2 -5	-71%	-$859	﹤0.01%	1542
2021 Q3	$1K	Buy	7 +2	+40%	+$441	﹤0.01%	1328
2021 Q2	$1K	Buy	5 +2	+67%	+$366	﹤0.01%	1330
2021 Q1	$1K	Buy	+3	New	+$598	﹤0.01%	1403

Other funds holding NVAX

SCM

Shah Capital Management Raleigh, North Carolina $605M AUM 43.69% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

CoreCap Advisors Southfield, Michigan $3.48B AUM 21.43% 1-Year Est. Return

Versant Capital Management's NVAX Position: Q3 2026 in Review

Versant Capital Management reduced its Novavax (NVAX) stake by 1.6% in Q3 2026, selling an estimated $99 and leaving 669 shares worth $7.23K. The position accounts for ﹤0.01% of the portfolio, ranked #2365.

Versant Capital Management first reported a position in NVAX in Q1 2021 and has held it in 10 quarters since. The position peaked at $10.2K in Q1 2026. 5 funds tracked by Wall St. Rank hold NVAX as of Q3 2026.

Versant Capital Management held 669 shares of Novavax worth $7.23K as of Q3 2026.
Versant Capital Management sold 11 Novavax shares in Q3 2026, an estimated $99.
Novavax made up ﹤0.01% of Versant Capital Management's portfolio in Q3 2026, its #2365 holding.
Versant Capital Management first reported a position in Novavax in Q1 2021 and has held it in 10 quarters since.
Versant Capital Management's Novavax position peaked at $10.2K in Q1 2026.
5 funds tracked by Wall St. Rank held Novavax as of Q3 2026.

Based on Versant Capital Management's 13F filing for Q3 2026, filed 2 Oct 2026.